http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0253777-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8c646f75c4f7c6349f35c8fe01934921 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-205 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195 |
| filingDate | 1987-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_725c0fed06157b87ebfd143c5994f497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80d14a07f84ada9e615986b431b86384 |
| publicationDate | 1988-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0253777-A2 |
| titleOfInvention | Use of L-carnitine for the manufacture of a medicament for the treatment of toxic effects induced by the inhalation of halothane and other halogen-containing general anesthetics. |
| abstract | Oral or parenteral administration of 10 to 30 mg/Kg/day of L-camitine (or an equivalent amount of a pharmacologically acceptable salt thereof) both during preanesthesia and postoperative phase antagonizes the toxic effects (particularly on kidneys and liver) induced by inhalation of halogen-containing general anesthetics such as; typically, halotane. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0722724-A1 |
| priorityDate | 1986-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.